| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 10/07/2004 | CA2560522A1 Use of compounds for the prevention of drug-induced cell toxicity |
| 10/07/2004 | CA2520440A1 Methods for treating or preventing an inflammatory or metabolic condition by inhibiting jnk |
| 10/07/2004 | CA2519694A1 Methods for treating lower urinary tract disorders using smooth muscle modulators and alpha-2-delta subunit calcium channel modulators |
| 10/07/2004 | CA2519682A1 Synergistic combination comprising roflumilast and an anticholinergic agent selected from ipratropium, oxitropium and tiotropium salts for the treatment of respiratory diseases |
| 10/07/2004 | CA2519155A1 Formulations comprising an active ingredient and cocoa powder and use thereof |
| 10/07/2004 | CA2519119A1 Formulations comprising tolterodine and cocoa powder and use thereof |
| 10/07/2004 | CA2519038A1 Oral delivery system comprising an antibacterial and an anti-inflammatory agent |
| 10/07/2004 | CA2518793A1 Methods of inducing immunotolerance and compositions for use therein |
| 10/06/2004 | EP1464330A1 Use of a composition containing oligosaccharides in combination with a saponine or a basic aminoacid, for topical administration or for inhalation |
| 10/06/2004 | EP1463928A2 Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer |
| 10/06/2004 | EP1463830A2 Method for classification of anti-psychotic drugs |
| 10/06/2004 | EP1463827A2 LIMKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| 10/06/2004 | EP1463823A2 Methods of increasing endogenous erythropoietin (epo) |
| 10/06/2004 | EP1463820A1 Method of screening compounds |
| 10/06/2004 | EP1463817A2 Histamine receptor h3 polynucleotides |
| 10/06/2004 | EP1463812A2 Degp protease: cleavage site identification and proteolysis of a natural target in e. coli |
| 10/06/2004 | EP1463806A2 Novel cyclooxygenase variants and methods of use |
| 10/06/2004 | EP1463804A1 Improved gamete recruitment and developmental competence in mammals by inhibiting the de novo sterol biosynthesis and/or promoting sterol efflux |
| 10/06/2004 | EP1463797A2 Methods of kidney transplantation utilizing developing nephric tissue |
| 10/06/2004 | EP1463760A2 Common lymphatic endothelial and vascular endothelial receptor-1 (clever-1) and uses thereof |
| 10/06/2004 | EP1463759A1 Ligand for g-protein coupled receptor gpr43 and uses thereof |
| 10/06/2004 | EP1463757A2 Antisense compounds directed against human csf-1 |
| 10/06/2004 | EP1463756A2 Secreted proteins |
| 10/06/2004 | EP1463733A2 Mitotic kinesin inhibitors |
| 10/06/2004 | EP1463730A1 Pyrazoloparidazine derivatives |
| 10/06/2004 | EP1463728A2 Fused cyclic modulators of nuclear hormone receptor function |
| 10/06/2004 | EP1463716A1 Pyrrolidine and piperidine derivates as nk1 antagonists |
| 10/06/2004 | EP1463715A1 Novel glucagon antagonists |
| 10/06/2004 | EP1463531A1 Methods for inhibiting ocular processes |
| 10/06/2004 | EP1463525A2 Compositions and methods for the diagnosis and treatment of tumor |
| 10/06/2004 | EP1463517A2 Analyse permettant de detecter des facteurs qui modulent l'expression d'ingap |
| 10/06/2004 | EP1463510A2 Administration of vasopeptidase inhibitors to reduce pulse pressure |
| 10/06/2004 | EP1463509A1 Type 4 phosphodiesterase inhibitors and uses thereof |
| 10/06/2004 | EP1463508A1 Selective dopamine d3 receptor agonists for the treatment of sexual dysfunction |
| 10/06/2004 | EP1463507A1 Thienopyrimidine compounds as protein tyrosine kinase inhibitors |
| 10/06/2004 | EP1463504A1 Compositions comprising epothilones and their use for the treatment of the carcinoid syndrome |
| 10/06/2004 | EP1463502A1 Broadspectrum heterocyclic substituted phenyl containing sulfonamide hiv protease inhibitors |
| 10/06/2004 | EP1463500A1 Use of cox-2 inhibitors in combination with antiviral agents for the treatment of papilloma virus infections |
| 10/06/2004 | EP1463499A1 Method for treating circadian rhythm disruptions |
| 10/06/2004 | EP1463498A1 Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases |
| 10/06/2004 | EP1463497A2 Treating muscle wasting with selective androgen receptor modulators |
| 10/06/2004 | EP1463496A2 Method for treating bronchial constriction and bronchospam |
| 10/06/2004 | EP1463495A2 Agents and methods for treatment of cancer |
| 10/06/2004 | EP1463493A1 Methods of inducing ovulation-using a non-polypeptide camp level modulator |
| 10/06/2004 | EP1463487A1 Liposomal delivery of vitamin e based compounds |
| 10/06/2004 | EP1463481A2 Methods and compositions for treatment of central nervous system disorders |
| 10/06/2004 | EP1463440A2 Prevention of flap necrosis in plastic surgery |
| 10/06/2004 | EP1463438A2 Endomural therapy |
| 10/06/2004 | EP1463408A2 Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin |
| 10/06/2004 | EP1383481B1 Process for manufacture of biofunctional hydroxyapatite coatings and microspheres for in-situ drug encapsulation |
| 10/06/2004 | EP1318837B1 Method of treating estrogen receptor positive carcinoma |
| 10/06/2004 | EP1307262B1 Method for locating compounds which are suitable for the treatment and/or prophylaxis of obesity |
| 10/06/2004 | EP1263300B1 Improvements in or relating to solubilisation of flavonols |
| 10/06/2004 | EP1210325B1 Aminobenzophenones as inhibitors of il-1beta and tnf-alpha |
| 10/06/2004 | EP1173147B1 Sunscreen agents containing hydroxycarboxylic acid alkyl,-and/or alkenyloligo- glycoside esters |
| 10/06/2004 | EP1133284B1 A process for the preparation of crystalline particles |
| 10/06/2004 | EP1101112B1 Leptin-mediated gene-induction |
| 10/06/2004 | EP1094797B1 Transdermal plaster containing at least one active ingredient which influences blood serum lipid levels |
| 10/06/2004 | EP1071955B1 Improved immunodiagnostic assays using reducing agents |
| 10/06/2004 | EP1032424B9 Combination of an aldose reductase inhibitor and a glycogen phosphorylase inhibitor |
| 10/06/2004 | EP1019096B1 Bioresorbable compositions for implantable prostheses |
| 10/06/2004 | CN1535168A Controlled release composition and method of producing the same |
| 10/06/2004 | CN1535161A Adenosine A2A receptor agonist and anticholinergic agent in combination for treating obstructive airways diseases |
| 10/06/2004 | CN1535160A Use of IL-18 inhibitors for treating or preventing CNS injuries |
| 10/06/2004 | CN1535151A Novel anti-infectives |
| 10/06/2004 | CN1535143A Use of MGLUR 5 antagonists for treatment of pruritic conditions |
| 10/06/2004 | CN1535140A Microparticle compositions and method for manufacture thereof |
| 10/06/2004 | CN1533808A Composition for treating coronavirus infection and SARS and method |
| 10/06/2004 | CN1533770A Saspension injection containing benzimidazole kind vermifuge |
| 10/06/2004 | CN1533764A Slow release injection preparation containing non sterol anti inflammation medicine |
| 10/06/2004 | CN1169524C Use of isotretinoin receptor antagonists for inhibition of mucin secretion and use of medicine for curing related diseases |
| 10/06/2004 | CN1169520C Perforated microparticles and methods for use |
| 10/06/2004 | CN1169514C Use of compound for improving skin and its mucous membrane physical-chemical property to prevent adsorption of microorganism |
| 10/05/2004 | US6800639 Dioxolane nucleosides and nucleoside analogues such as troxacitabine together with chemotherapeutic agents other than doxorubicin such as cytarabine, gemcitabine and idarubicin; synergistic mixture; treating leukemia, cancer |
| 10/05/2004 | US6800632 Bicyclic inhibitors of glycogen synthase kinase 3 |
| 10/05/2004 | US6800624 Sulfonamide and sulfamide substituted imidazoquinolines |
| 10/05/2004 | US6800605 With a hypolipidemic agent, an antidiabetic agent, an antidepressant, a bone resorption inhibitor, an appetite suppressant and/or an anti-obesity agent |
| 10/05/2004 | US6800483 Compositions and methods for sensitizing and inhibiting growth of human tumor cells |
| 10/05/2004 | US6800471 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 10/05/2004 | US6800470 Mammalian sphingosine kinase type 2 isoforms, cloning, expression and methods of use thereof |
| 10/05/2004 | US6800446 Therapeutic and diagnostic methods for ulcerative colitis and associated disorders |
| 10/05/2004 | US6800434 Peptides as NS3-serine protease inhibitors of hepatitis C virus |
| 10/05/2004 | US6800303 Process of making a supplement for digestive ailment |
| 10/05/2004 | US6800301 Reduces the healing and recovery time of skin that has been damaged |
| 10/05/2004 | US6800292 Free radical neutralization; includes moisturizers |
| 10/05/2004 | US6800290 Variants can be used in specific immunotherapy of allergic pathologies caused by dust mites |
| 10/04/2004 | CA2463115A1 Anti-inflammatory composition |
| 09/30/2004 | WO2004083382A2 Compositions and methods for treating hyperimmune response in the eye |
| 09/30/2004 | WO2004082749A2 Medical devices with enhanced ultrasonic visibility |
| 09/30/2004 | WO2004082719A1 Dispersible pharmaceutical composition for treatment of mastitis and otic disorders |
| 09/30/2004 | WO2004082716A1 PHENYLCARBOXYL ACID AMIDES AND IKr CHANNEL INHIBITORS COMBINATION AND THE USE THEREOF FOR TREATING ATRIAL ARRHYTHMIA |
| 09/30/2004 | WO2004082715A1 Concomitant drug as therapeutic agent for inflammatory bowel disease |
| 09/30/2004 | WO2004082706A2 Ifn-beta alone or in combination with other medicaments for treating alzheimer's disease and demens disorders |
| 09/30/2004 | WO2004082692A1 Actacid composition |
| 09/30/2004 | WO2004082689A1 Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor |
| 09/30/2004 | WO2004082674A1 Carnitine retention |
| 09/30/2004 | WO2004082669A2 Antiflatulents in combibation with histamine h1-receptor antagonist for treating gastrointestinal disoders |
| 09/30/2004 | WO2004082664A1 Water-soluble tablets of metformin |
| 09/30/2004 | WO2004082637A2 Combination of an aldosterone receptor antagonist and an endothelin receptor antagonist and/or endothelin converting enzyme inhibitor |
| 09/30/2004 | WO2004082636A2 Combination of an aldosterone receptor antagonist and a neutral endopeptidase inhibitor |